CTI BioPharma Other Liabilities

CTI BioPharma (CTIC) currently reports a other liabilities of $0 as of March 2023. That compares with $1.8M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore CTI BioPharma's other liabilities history and peer comparisons.

CTI BioPharma's other liabilities decreased from $1.8M to $0 — a 100.0% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CTI BioPharma reported $0 in other liabilities as of March 2023. That compares with $1.8M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CTI BioPharma, and consider following CTIC for alerts when major investors trade the stock.

CTI BioPharma is classified in the Healthcare sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CTIC with unrelated industries.